• No results found

Tofacitinib, an oral janus kinase inhibitor: pooled efficacy and safety analyses in an Australian rheumatoid arthritis population

N/A
N/A
Protected

Academic year: 2019

Share "Tofacitinib, an oral janus kinase inhibitor: pooled efficacy and safety analyses in an Australian rheumatoid arthritis population"

Copied!
19
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Baseline demographics and disease characteristics of the Australian subpopulation (phase III and LTE studies)
Fig. 2 PROs in the pooled phase III study populationshowing the mean changes from baseline a across eight SF-36 domain scores at month 3, b in SF-36 PCS to month12, and c in SF-36 MCS to month 12 (FAS, noimputation)
Table 2 Summary of AEs, discontinuations due to AEs, SAEs, and AEs of special interest during the phase III studies andthe LTE
Table 3 Summary of the most commonly reported AEs (C 5% in any tofacitinib group) during the phase III studies andthe LTE study, and AEs of special interest during the LTE study
+4

References

Related documents

Our current data validate the high activity of these bis-AIA scaffolds that exhibited EC 50 (drug concentration that reduces 50% of the number of the treated parasites)

a) In all years of observations (T Karski 1984-2018), it was confirmed the biomechanical etiology of the so-called idiopathic scoliosis. b) Development of scoliosis and

CI: confidence interval; DM: diabetes mellitus; HR: hazard ratio; ICD‑10: Inter‑ national Statistical Classification of Diseases and Related Health Problems 10th Revision;

Operational matrices of integration, differentiation and product are introduced and utilized to reduce the solution of optimal control problems with time-varying

Interestingly, in another Canadian study, Kwong asked this question and found the opposite—25% of first-year students felt that financial considerations would be a

d Real-time RT-PCR showing that L-NMMA treatment significantly reduced runt-related transcription factor 2 (Runx2), osterix (OSX), and osteopontin (OPN) mRNA expression levels,